Cydan is a venture-backed orphan drug accelerator that was founded in 2013 and is based in Cambridge MA. The firm has raised a second fund of $34 million dollars to derisk therapeutic assets targeting orphan indications (excluding oncology). The firm looks to option/in-license assets from entrepreneurs, biotech, pharma companies and research institutions and form new companies dedicated to the development of these assets in orphan indications. Cydan derisks the assets by conducting studies and activities necessary to advance the program to a stage where it can be served as a foundation for a NewCo. Cydan II’s investment syndicate includes NEA, Longitude Capital, Pfizer Ventures, Lundbeckfond Ventures, and Alexandria Real Estate Equities, Inc. This syndicate is committed to funding the new companies that Cydan creates up to and including human proof-of-principle. Recent examples of Cydan projects that became companies include Vtesse (acquired by Sucampo/Malinckrodt), which is developing a Phase III drug for Niemann Pick C and Imara, which is developing a Phase II product for sickle cell disease. Cydan is currently considering pre–clinical and clinical assets worldwide.